Eletriptan

Evidence Level: L5

Predicted Indications: 3

Eletriptan

Pharmacist Assessment Report

Eletriptan: 5-HT1B/1D receptor agonist (triptan) → atrophoderma vermiculata

One-Sentence Summary

Eletriptan is a triptan-class serotonin receptor agonist. The TxGNN model predicts it may be relevant to atrophoderma vermiculata, but no clinical trials and no publications currently support this direction, so the prediction is computational only.

Quick Overview

Item	Content
Original Indication	Not recorded in the local data
Predicted New Indication	atrophoderma vermiculata
TxGNN Prediction Score	0.9994
Evidence Level	L5
India Market Status	Listed in a compiled Indian medicine price dataset (2 of 2) – CDSCO approval status is not included in this data
Number of Listed Products	2 (valid: 2)
Recommended Decision	Hold

Why is This Prediction Reasonable?

Detailed mechanism of action data is not available in the data compiled for this report. Eletriptan belongs to the triptan class, which acts as an agonist at 5-HT1B/1D receptors.

Atrophoderma vermiculata is a rare follicular atrophic skin disorder. No identifiable mechanistic link connects serotonin receptor agonism to its pathology. The high model score appears to be an artifact of the computational method rather than a reflection of biological plausibility.

For context, two other predictions were generated for this drug (ulerythema ophryogenesis, score 0.9989, and sciatic neuropathy, score 0.9903). Both also lack trials and literature. The first is likely driven by its similarity to atrophoderma vermiculata, and the second rests only on a speculative link to peripheral pain pathways.

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

Currently no related literature available.

India Market Information

Authorization Number	Product Name	Dosage Form	Approved Indication
75328	Elipran 20 Tablet	Strip of 4 tablets	Not recorded
74429	Elipran 40 Tablet	Strip of 4 tablets	Not recorded

Both licences are single-ingredient products and currently valid. The manufacturer is Intas Pharmaceuticals Ltd. The available dosage form is oral.

Safety Considerations

Contraindication-related conditions (not label text): The data compiled for this report flag several conditions where use is of concern, mainly cardiovascular and cerebrovascular: hypertension, coronary artery disease, myocardial infarction, myocardial ischemia, Prinzmetal angina, stroke and transient ischemic attack, peripheral vascular disease, Raynaud disease, ischemic bowel disease, and vertebrobasilar insufficiency. Other flagged conditions include liver disease and liver failure, gallbladder disease, diabetes and diabetic ketoacidosis, obesity, hemoglobinopathy, serotonin syndrome, and hemiplegic migraine.
Drug Interactions: 94 interactions were recorded. Major-level examples include clarithromycin, lorcaserin, fenfluramine, dexfenfluramine, sibutramine, and the 5-HT3 antagonists ondansetron, granisetron, dolasetron and palonosetron. Moderate-level examples include aprepitant, morphine, cimetidine, clotrimazole and miconazole.

Please refer to the package insert for the full warnings, as label text was not available in the compiled data.

Conclusion and Next Steps

Decision: Hold

Rationale: The prediction has a high model score but no trials, no literature and no plausible mechanistic link. Evidence is at L5 (model prediction only).

To proceed, the following is needed:

A credible mechanistic hypothesis linking 5-HT1B/1D agonism to atrophoderma vermiculata
Preclinical or case-level evidence in this condition
Package insert warnings and contraindications from the Indian licences
Detailed mechanism of action data
A cardiovascular risk assessment, given the flagged contraindication-related conditions and the major interactions
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.